carmofur has been researched along with Breast Cancer in 19 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We studied the usefulness of the oral 5-FU anti-cancer drug 1-hexylcarbamoyl-5-fluorouracil (HCFU) + cyclophosphamide (CPM) + tamoxifen (TAM) (HCT group) in comparison with CMF + TAM (CMFT group) in adjuvant therapy for breast cancer by a non-inferiority study based on a multi-institutional joint study." | 9.11 | 1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial. ( Abe, R; Aoyama, H; Asaga, T; Awane, H; Danno, M; Ikeda, T; Kimura, M; Koyama, H; Mitsuyama, S; Nishi, T; Ogita, M; Sano, M; Takashima, S; Takatsuka, Y; Toi, M; Tominaga, T; Wada, T; Yoshida, M, 2004) |
| "The efficacy of oral fluoropyrimidine carmofur was evaluated for adjuvant use for breast cancer." | 9.10 | Postoperative adjuvant use of carmofur for early breast cancer. ( Koh, M; Morimoto, K, 2003) |
| "The direct effect and safety of carmofur (Mifurol) in cases of advanced and recurrent breast cancer were evaluated as a cooperative study at twenty-two facilities nationwide." | 9.08 | [Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer]. ( Abe, R; Enomoto, K; Koyama, H; Kusama, M; Nishi, T; Sonoo, H; Takashima, S; Tominaga, T; Yamaguchi, S; Yoshida, M, 1995) |
| "The purpose of this study is to determine the characteristic clinical features, radiologic findings, and precipitating and prognostic factors in the patients with breast cancer and with 5-Fluorouracil (5-FU)-induced leukoencephalopathy." | 7.71 | 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. ( Cho, KH; Choi, SM; Kim, BC; Kim, MK; Lee, SH; Yang, YS, 2001) |
| "We studied the usefulness of the oral 5-FU anti-cancer drug 1-hexylcarbamoyl-5-fluorouracil (HCFU) + cyclophosphamide (CPM) + tamoxifen (TAM) (HCT group) in comparison with CMF + TAM (CMFT group) in adjuvant therapy for breast cancer by a non-inferiority study based on a multi-institutional joint study." | 5.11 | 1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial. ( Abe, R; Aoyama, H; Asaga, T; Awane, H; Danno, M; Ikeda, T; Kimura, M; Koyama, H; Mitsuyama, S; Nishi, T; Ogita, M; Sano, M; Takashima, S; Takatsuka, Y; Toi, M; Tominaga, T; Wada, T; Yoshida, M, 2004) |
| "The efficacy of oral fluoropyrimidine carmofur was evaluated for adjuvant use for breast cancer." | 5.10 | Postoperative adjuvant use of carmofur for early breast cancer. ( Koh, M; Morimoto, K, 2003) |
| "The direct effect and safety of carmofur (Mifurol) in cases of advanced and recurrent breast cancer were evaluated as a cooperative study at twenty-two facilities nationwide." | 5.08 | [Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer]. ( Abe, R; Enomoto, K; Koyama, H; Kusama, M; Nishi, T; Sonoo, H; Takashima, S; Tominaga, T; Yamaguchi, S; Yoshida, M, 1995) |
| "The purpose of this study is to determine the characteristic clinical features, radiologic findings, and precipitating and prognostic factors in the patients with breast cancer and with 5-Fluorouracil (5-FU)-induced leukoencephalopathy." | 3.71 | 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. ( Cho, KH; Choi, SM; Kim, BC; Kim, MK; Lee, SH; Yang, YS, 2001) |
| "Carmofur (1-hexylcarbamyl-5-fluorouracil), a derivative of 5-fluorouracil (5-FU), has been widely used in Japan as a postoperative adjuvant chemotherapy agent for colorectal and breast cancer." | 3.71 | Diffusion-weighted MR imaging of Carmofur-induced leukoencephalopathy. ( Fujikawa, A; Hachiya, J; Katase, S; Kurosaki, Y; Tsuchiya, K, 2001) |
| "S-1 could be a valuable agent for breast cancer treatments, since it showed clinical efficacy and mild toxicity, and can be given orally." | 1.33 | S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer. ( Aogi, K; Doihara, H; Nishimura, R; Ohsumi, S; Saeki, T; Taira, N; Takashima, S, 2006) |
| "A case of toxic leucoencephalopathy induced by 5 FU derivatives is reported." | 1.27 | [A case of toxic leucoencephalopathy induced by 5FU derivatives]. ( Ishijima, B; Mizutani, T; Morimatsu, Y; Sato, J; Yasue, M, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (31.58) | 18.7374 |
| 1990's | 5 (26.32) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morimoto, K | 1 |
| Koh, M | 1 |
| Tominaga, T | 4 |
| Kimura, M | 2 |
| Asaga, T | 1 |
| Yoshida, M | 3 |
| Awane, H | 1 |
| Koyama, H | 2 |
| Takatsuka, Y | 1 |
| Mitsuyama, S | 1 |
| Ikeda, T | 1 |
| Ogita, M | 1 |
| Aoyama, H | 1 |
| Sano, M | 2 |
| Abe, R | 2 |
| Nishi, T | 3 |
| Wada, T | 1 |
| Danno, M | 2 |
| Toi, M | 1 |
| Takashima, S | 4 |
| Taira, N | 1 |
| Aogi, K | 1 |
| Ohsumi, S | 1 |
| Nishimura, R | 1 |
| Doihara, H | 1 |
| Saeki, T | 1 |
| Koyama, Y | 2 |
| Kusama, M | 1 |
| Enomoto, K | 1 |
| Sonoo, H | 1 |
| Yamaguchi, S | 1 |
| Katsumata, K | 1 |
| Yamashita, S | 1 |
| Hoshino, S | 1 |
| Tani, C | 1 |
| Yamamoto, K | 1 |
| Kimura, K | 1 |
| Matsumoto, S | 1 |
| Nishizawa, S | 1 |
| Murakami, M | 1 |
| Noma, S | 1 |
| Sano, A | 1 |
| Kuroda, Y | 1 |
| Miyauchi, M | 1 |
| Yamamoto, N | 1 |
| Matsumoto, M | 1 |
| Shishikura, T | 1 |
| Hyakutake, K | 1 |
| Choi, SM | 1 |
| Lee, SH | 1 |
| Yang, YS | 1 |
| Kim, BC | 1 |
| Kim, MK | 1 |
| Cho, KH | 1 |
| Sasaki, M | 1 |
| Yoshida, K | 1 |
| Asano, T | 1 |
| Fujiwara, J | 1 |
| Osako, Y | 1 |
| Fujikawa, A | 1 |
| Tsuchiya, K | 1 |
| Katase, S | 1 |
| Kurosaki, Y | 1 |
| Hachiya, J | 1 |
| Fukushima, K | 1 |
| Okawa, T | 1 |
| Ikeda, M | 1 |
| Mikuriya, S | 1 |
| Hashimoto, S | 1 |
| Amino, S | 1 |
| Horiuchi, J | 1 |
| Matsuda, T | 1 |
| Ebata, K | 1 |
| Kaneda, K | 1 |
| Aoki, N | 1 |
| Yasue, M | 1 |
| Ishijima, B | 1 |
| Sato, J | 1 |
| Mizutani, T | 1 |
| Morimatsu, Y | 1 |
| Tanaka, R | 1 |
| Fukushima, H | 1 |
| Sato, K | 1 |
| Matsuda, M | 1 |
| Hanaoka, T | 1 |
| Goya, T | 1 |
1 review available for carmofur and Breast Cancer
| Article | Year |
|---|---|
[Recent development of oral anti-cancer drugs for breast cancer].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clin | 1999 |
6 trials available for carmofur and Breast Cancer
| Article | Year |
|---|---|
Postoperative adjuvant use of carmofur for early breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carbazilquinone; Chemotherapy, Adjuvant; Femal | 2003 |
1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Ch | 2004 |
1-Hexylcarbamoyl-5-fluorouracil (HCFU)--a masked 5-fluorinated pyrimidine.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Breast Neoplasms; Cats; Clinical Trials as Topic; Femal | 1981 |
[Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Dizziness; Dru | 1995 |
[Comparative clinical study on 5-FU concentrations for oral HCFU and i.v. 5-FU].
Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Cross-Over Studies; Drug Administrati | 2000 |
Postoperative chemoendocrine therapy for women with node-positive stage II breast cancer with combined cyclophosphamide, tamoxifen, and 1-hexylcarbamoyl-5-fluorouracil.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Ne | 2001 |
12 other studies available for carmofur and Breast Cancer
| Article | Year |
|---|---|
S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplas | 2006 |
[Phase II study of carmofur (HCFU) fine granules].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Child; Child, Preschool; Colonic N | 1982 |
[Evaluation of neoadjuvant combination chemotherapy with pirarubicin, carmofur and tamoxifen citrate on outpatients with advanced and recurrence breast cancer].
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherap | 1994 |
Carmofur-induced leukoencephalopathy: MRI.
Topics: Antineoplastic Agents; Brain; Brain Damage, Chronic; Breast Neoplasms; Chemotherapy, Adjuvant; Demye | 1995 |
5-fluorouracil-induced leukoencephalopathy in patients with breast cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Brain; Breast Neop | 2001 |
[A case of reversible carmofur-induced leukoencephalopathy].
Topics: Adult; Antineoplastic Agents; Brain; Brain Diseases; Breast Neoplasms; Female; Fluorouracil; Humans; | 2001 |
Diffusion-weighted MR imaging of Carmofur-induced leukoencephalopathy.
Topics: Adult; Antineoplastic Agents; Brain; Brain Diseases; Breast Neoplasms; Carcinoma, Ductal, Breast; Ch | 2001 |
[Antitumor effects of 5-fluorouracil-bound organic silicon compound].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Ethyla | 1989 |
[A clinical study of radiotherapy with HCFU for advanced and recurrent breast cancers. Radiation and HCFU Study Group for breast cancer].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Eval | 1985 |
Reversible leukoencephalopathy caused by 5-fluorouracil derivatives, presenting as akinetic mutism.
Topics: Anal Gland Neoplasms; Animals; Breast Neoplasms; Carcinoma; Female; Fluorouracil; Humans; Leukoencep | 1986 |
[A case of toxic leucoencephalopathy induced by 5FU derivatives].
Topics: Antineoplastic Agents; Brain; Brain Diseases; Breast Neoplasms; Female; Fluorouracil; Humans; Middle | 1985 |
[Successful endocrine chemotherapy in patients with multiple bone metastases of breast cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Modality | 1999 |